SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?

ETFs in Focus as U.S. Economy Rebounds in Q2 

U.S. GDP grew 3% in Q2 2025, beating forecasts and easing recession fears as investors eye VTV, XLU, DVY, DFUV and SPYD.

Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?

Comerica (CMA) shares fell 5% on Wednesday after the company missed the Wall Street estimate for fourth-quarter earnings.The lender reported an adjusted net earnings of $1.20 per share for the October to December quarter, compared with average analysts’ estimate of $1.26 per share, according to FinChat data.Its net interest income (NII) fell marginally to $575 million compared to last year.“Loans were pressured by paydowns in Commercial Real Estate, but we saw promising signals across other businesses that support our outlook for growth in 2025,” CEO Curtis C. Farmer said in a statement.The bank said that loans decreased $244 million to $50.6 billion sequentially during the fourth quarter, driven lower by a $225 million decline in Commercial Real Estate and a $132 million fall in Corporate Banking. These were partially offset by a $116 million increase in Energy loans.The Dallas-based company added that its deposits fell $549 million to $63.3 billion compared to the third quarter of 2024.<a href="https://stocktwits.com/symbol/CMA">Comerica</a>, which is also present in Canada and Mexico, said its provision for credit losses rose to $21 million from $14 million, sequentially.However, its net interest margin rose by 26 basis points to 3.06% compared to the third-quarter.Retail sentiment on Stocktwits remained in the ‘neutral’ (53/100) territory, while retail chatter rose to ‘ extremely high.’<figure class="image"><img style="aspect-ratio:816/195;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CMA_Jan_22_a5460d158c.JPG" alt="CMA’s Sentiment Meter and Message Volume as of 02:52 p.m. ET on Jan. 22, 2025 | Source: Stocktwits" width="816" height="195"><figcaption>CMA’s Sentiment Meter and Message Volume as of 02:52 p.m. ET on Jan. 22, 2025 | Source: Stocktwits</figcaption></figure>Last week, Wall Street’s major banks, including JP Morgan &amp; Chase, Wells Fargo, Bank of America, and Citigroup, all topped market expectations for quarterly profit.Over the past year, the stock has gained 20.3%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/3-m-stock-gains-after-flurry-of-price-target-hikes/chbe7RyR8W">3M Stock Gains After Flurry Of Price Target Hikes: Retail Continues To Be Jubilant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Comerica Bank building facade with blue signage and brick exterior, Walnut Creek, California, March 30, 2023. (Photo by Smith Collection/Gado/Getty Images)

Comerica Stock Drops On Q4 Earnings Miss, Retail Reaction Split

The lender reported an adjusted net earnings of $1.20 per share for the October to December quarter, compared with average analysts’ estimate of $1.26 per share, according to FinChat data.

Equity

Shares of refiner Valero Energy Corporation ($VLO) rose nearly 1% in Thursday’s premarket session after the firm’s third-quarter (Q3) earnings and revenue topped Wall Street estimates.The firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20241023908536/en/Valero-Energy-Reports-Third-Quarter-2024-Results">reported</a> a 14% year-over-year (YoY) decline in its Q3 revenues to $32.87 billion compared to a Wall Street estimate of $31.13 billion. Adjusted earnings per share (EPS) came in at $1.14 versus an estimate of $0.98. Net income, however, slid over 86% YoY to $364 million during the quarter.Refining margins came in at $2.41 billion during the quarter compared to $5.41 billion in the same quarter a year ago.The firm’s refining segment reported Q3 operating income of $565 million, compared to $3.4 billion for the same period a year ago.The Renewable Diesel segment reported $35 million of operating income compared to $123 million for the third quarter of 2023. Meanwhile, the Ethanol segment saw $153 million of operating income versus $197 million for the third quarter of 2023.The company returned $907 million to stockholders in Q3, of which $342 million was paid as dividends while $565 million was used for the purchase of approximately 3.8 million shares of common stock.As of the end of the third quarter, the company has $8.4 billion of total debt, $2.5 billion of finance lease obligations, and $5.2 billion of cash and cash equivalents.Valero highlighted that its SAF project at the DGD Port Arthur plant was completed in October and is expected to be fully operational this year.Following the earnings release, retail sentiment on Stocktwits inched up into the ‘bullish’ territory (58/100), supported by high retail chatter.<figure class="image"><a href="https://stocktwits.com/symbol/VLO"><img style="aspect-ratio:1870/514;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_24_at_7_57_34_AM_09cd0d42bf.png" alt="Valero Energy’s sentiment meter as of 7:37 a.m. ET on Oct. 24, 2024 | Source: Stocktwits" width="1870" height="514"></a><figcaption>Valero Energy’s sentiment meter as of 7:37 a.m. ET on Oct. 24, 2024 | Source: Stocktwits</figcaption></figure>Shares of Valero Energy have gained just about 1.7% this year so far.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/keurig-dr-pepper-to-acquire-energy-drink-maker-ghost/cJ21N0MR7J">Keurig Dr Pepper To Acquire Energy Drink-Maker Ghost For Nearly $1B: Retail Sentiment Inches Higher</a>For updates and corrections email newsroom@stocktwits.com

Adjusted earnings per share (EPS) came in at $1.14 versus an estimate of $0.98 | Image Source: Valero

Valero Energy Stock Rises Pre-Market After Upbeat Q3 Print: Retail Ignores Big Profit Decline 

The firm reported a 14% year-over-year (YoY) decline in its Q3 revenues to $32.87 billion compared to a Wall Street estimate of $31.13 billion.

Fifth Third Bancorp’s stock ($FITB) was down nearly 1.7% &nbsp;in pre-market trading after the company’s third-quarter earnings per share (EPS) and revenue missed Wall Street estimates. Retail sentiment, however, was neutral on Stocktwits.Fifth Third posted $0.78 in EPS, below the $0.83 estimated by analysts. Its revenue stood at $2.13 billion, below the expected $2.16 billion.Net income fell 13% to $573 million compared to the same period last year. Its net interest income fell 1% from a year-ago quarter to $1.43 billion.Retail sentiment was neutral (53/100) compared to ‘extremely bullish’ (79/100) a day ago. Message volume, meanwhile, was ‘high’. (63/100).<figure class="image"><img style="aspect-ratio:1338/384;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_18_at_6_07_58_PM_24c7f77714.png" alt="Screenshot 2024-10-18 at 6.07.58 PM.png" width="1338" height="384"><figcaption>FITB sentiment meter as of 8:38 am ET| Source: Stocktwits<a href="https://stocktwits.com/symbol/FITB">https://stocktwits.com/symbol/FITB</a></figcaption></figure>“With our strong core deposit franchise and liquidity, we are well positioned for the declining interest rate environment and volatility driven by the economic and regulatory uncertainty,” Tim Spence, Fifth Third Chairman, CEO and President, said in a statement.“Our strategic growth priorities continue to deliver strong results. In the Southeast, where we are expanding into high-growth markets, deposits grew by 16% over the last twelve months.”It increased its quarterly cash dividend on its common shares by $0.02, or 6%, to $0.37 per share for the third quarter of 2024, the company said.The bank claims deposits grew by 16% in high-growth markets in the Southeast over the last 12 months.Its wealth and asset management business also appear to be strong with assets under management growing 21% year-over-year to $69 billion.Fifth Third stock is up 30.4% year-to-date.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Its net interest income fell 1% from a year-ago quarter to $1.43 billion.

Fifth Third Bancorp Stock Falls After Earnings Miss Estimates: Retail Neutral

Fifth Third Bancorp posted $0.78 in EPS, below the $0.83 estimated by analysts

Citizens Financial Group stock was down 1.1% pre market (7:42 am ET) after its third quarter profit fell 11.8% from a year ago, with retail sentiment turning bearish.Its earnings per share (EPS) stood at $0.77, below the $0.79 estimated by analysts, on revenues of $1.9 billion, down 5.7% from the same quarter last year. Analysts had estimated $1.94 billion in revenues.The Providence, RI-based-based bank also posted a steep dip in net interest income to $1.4 billion, down 10% from last year, partly due to lower net interest margin and a 1% decline in average interest earning assets, the bank said in a statement.Retail sentiment was ‘bearish’ (41/100) and messages volumes in the ‘extremely high’ zone.<figure class="image"><img style="aspect-ratio:1338/384;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_16_at_4_45_28_PM_9bc1dcc652.png" alt="Screenshot 2024-10-16 at 4.45.28 PM.png" width="1338" height="384"><figcaption>CFG sentiment meter as of 7:16 am| Source: Stocktwits</figcaption></figure>“We continue to be pleased with the strong execution of our key initiatives during the third quarter,” Chairman and CEO Bruce Van Saun said in the statement. “Our Private Bank reached $5.6 billion in deposits and $4.1 billion in AUM, our NYC Metro region continues to achieve strong growth, and we are close to launching a TOP 10 program with $100 million plus impact.”Van Saun added the bank’s balance sheet remains strong across capital, liquidity, funding and loan loss reserves. However, the quarter was hit by forward starting swaps that began in July, and fees pushed out to the next quarter.Van Saun predicts a “strong fourth quarter and launch into 2025.”Citizens has also announced a quarterly common stock dividend of $0.42 per share.&nbsp;

CFG Stock Falls Pre-Market After Profit Misses Estimates: Retail Bearish 

The Providence, RI-based-based bank also posted a steep dip in net interest income to $1.4 billion, down 10% from last year.

Shares of Walgreens Boots Alliance Inc. ($WBA) surged more than 5% pre-market Tuesday after the company reported better-than-expected earnings and revealed a significant store closure plan.Walgreens earned $0.39 per share on an adjusted basis in its fiscal fourth quarter, exceeding analysts’ average estimate of $0.36 per share.The company’s revenue climbed 6% year-over-year to $37.5 billion, topping expectations of $35.8 billion.In addition to its earnings beat, Walgreens announced a three-year “footprint optimization program” targeting approximately 1,200 store closures — about 14% of its U.S. locations — including 500 closures planned for fiscal 2025.The company believes this move will be immediately accretive to adjusted earnings per share (EPS) and free cash flow.“Fiscal 2025 will be an important rebasing year as we advance our strategy to drive value creation. This turnaround will take time, but we are confident it will yield significant financial and consumer benefits over the long term,” said CEO Tim Wentworth.Walgreens provided a fiscal 2025 earnings forecast of $1.40 to $1.80 per share, against a consensus estimate of $1.72.For full-year sales, the company expects revenue between $147 billion and $151 billion, aligning with analysts’ expectations of $147.6 billion.The company’s U.S. healthcare and international businesses are expected to grow, while its U.S. retail pharmacy division is projected to face continued challenges.<figure class="image"><a href="https://stocktwits.com/symbol/WBA"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/WBA_sentiment_and_message_volume_Oct_15_premarket_d2c9c06ae3.png" alt="WBA sentiment and message volume Oct 15 premarket.png" width="1314" height="320"></a><figcaption>WBA sentiment and message volume Oct 15 premarket as of 8:45 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for WBA turned ‘bullish’ in pre-market trading, with a noticeable increase in message volume.<stembedurl>https://stocktwits.com/bc4/message/588938268</stembedurl><stembedurl>https://stocktwits.com/taurus_bullish/message/588938537</stembedurl>Earlier, CEO Wentworth had warned that headwinds would persist into 2025 as the retail pharmacy division faces stiff competition from e-commerce giants like Amazon and discount retailers such as Dollar General and Costco.WBA stock is still down more than 66% year-to-date.Read next: <a href="https://stocktwits.com/news-articles/markets/equity/unh-stock-falls-after-q3-earnings/cJcwH6bR4Z">UnitedHealth Group’s Stock Falls Pre-Market As Higher Medical Costs Eat Into Profits: Here’s How Retail Is Reacting</a>

Walgreens announced a three-year “footprint optimization program” targeting approximately 1,200 store closures.

WBA Stock Climbs On Plan To Close Thousands of Stores: Retail Is Betting On A Comeback

The company’s U.S. healthcare and international businesses are expected to grow, while its U.S. retail pharmacy division is projected to face continued challenges.

DVY
iShares Select Dividend ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DVY News

DVYiShares Select Dividend ETF